Elevated lipoprotein(a) represents one of the most prevalent residual risk factors in modern preventive cardiology. Consequently, the rapid emergence of novel lipoprotein a therapies marks a transformative shift toward targeted cardiovascular protection. Epidemiological and genetic studies consistently demonstrate that elevated lipoprotein(a) levels independently drive atherosclerotic cardiovascular disease and calcific aortic valve stenosis. Because plasma concentrations are largely determined by genetics, traditional lifestyle changes and standard lipid-lowering drugs fail to achieve clinically meaningful reductions. However, recent clinical developments offer substantial promise. Innovative nucleic acid platforms and small-molecule inhibitors now achieve profound, selective reductions in circulating concentrations. Clinicians worldwide are eagerly following late-stage clinical trials that evaluate whether these reductions effectively lower cardiovascular event rates. As cardiovascular outcomes trials progress toward completion, clinicians must understand the mechanisms, clinical data, and emerging evidence behind these transformative interventions.

Biological Role and Cardiovascular Burden of Lipoprotein(a)

Lipoprotein(a) consists of an apolipoprotein B-100 containing low-density lipoprotein particle covalently bound to apolipoprotein(a). Therefore, this hybrid particle exhibits both proatherogenic and prothrombotic properties. It accelerates vascular inflammation, endothelial dysfunction, and foam cell formation through oxidized phospholipids carried on its structure. In addition, its structural homology to plasminogen allows it to impair fibrinolysis, thereby promoting thrombogenesis. Genetic studies indicate that plasma concentrations are seventy to ninety percent heritable. Unlike low-density lipoprotein cholesterol, circulating concentrations remain remarkably constant throughout life regardless of diet or exercise. Furthermore, standard pharmacotherapies like statins do not lower concentrations and may paradoxically increase them slightly. Although PCSK9 inhibitors provide modest reductions of fifteen to twenty-five percent, these changes are often insufficient to mitigate cardiovascular risk. Consequently, patients with severe elevations remain exposed to substantial lifelong atherothrombotic danger. Clinicians increasingly recognize that specifically lowering apolipoprotein(a) production represents the only definitive therapeutic strategy.

Antisense Oligonucleotides: Pelacarsen and the Phase 3 HORIZON Trial

Antisense oligonucleotides represent the pioneering class of RNA-targeted therapeutics designed to disrupt hepatic apolipoprotein(a) synthesis. Specifically, pelacarsen is an advanced, GalNAc-conjugated antisense oligonucleotide that selectively targets hepatocyte apolipoprotein(a) messenger RNA. By facilitating RNase H-mediated RNA degradation, pelacarsen dramatically suppresses hepatic apolipoprotein(a) translation before particle assembly occurs. In phase 2 dose-finding clinical trials, monthly subcutaneous administration of pelacarsen produced dose-dependent reductions in lipoprotein(a) of up to eighty percent. Moreover, the therapy demonstrated favorable tolerability, with injection-site reactions representing the primary adverse event. Currently, the pivotal phase 3 Lp(a) HORIZON cardiovascular outcomes trial is evaluating whether pelacarsen reduces major adverse cardiovascular events in over eight thousand patients with established vascular disease. Importantly, results expected in late 2026 will determine whether significant pharmacological reduction definitively lowers recurrent ischemic events. Thus, pelacarsen could soon become the first regulatory-approved targeted agent in cardiovascular risk management.

Small Interfering RNA Agents: Olpasiran, Lepodisiran, and Zerlasiran

Small interfering RNA molecules offer another powerful modality for durable gene silencing in the liver. Like antisense oligonucleotides, these agents utilize GalNAc conjugation to achieve targeted hepatocyte uptake via asialoglycoprotein receptors. Inside hepatocytes, these double-stranded RNAs load into the RNA-induced silencing complex to catalyze catalytic degradation of target transcripts. Olpasiran has shown remarkable potency, reducing circulating levels by more than ninety-five percent at highest doses in the phase 2 OCEAN(a)-DOSE study. The ongoing phase 3 OCEAN(a)-Outcomes trial is rigorously evaluating its clinical efficacy on cardiovascular morbidity. Similarly, lepodisiran has demonstrated durable efficacy, achieving a 93.9 percent reduction that persists for over twelve months after a single dose in clinical trials. Zerlasiran has also documented reductions exceeding ninety-six percent with quarterly or biannual administration schedules. Consequently, these siRNA therapies provide exceptional sustained target suppression, potentially requiring dosing only two to four times per year.

Small Molecule Inhibitors and Gene Editing Frontiers

While RNA-based injectable therapeutics dominate the pipeline, researchers are also pursuing oral formulations and permanent genetic edits. Muvalaplin represents a groundbreaking advance as the first oral small-molecule inhibitor of lipoprotein(a) assembly. Mechanistically, muvalaplin selectively binds to the kringle IV domains of apolipoprotein(a), effectively blocking non-covalent interaction with apolipoprotein B-100. By preventing initial particle assembly, muvalaplin decreased intact lipoprotein(a) concentrations by up to 85.8 percent in the phase 2 KRAKEN study. Phase 3 cardiovascular outcomes evaluations with the MOVE-Lp(a) trial are currently enrolling participants. Beyond small molecules, therapeutic genome editing has officially entered human trials. The CTX320 program utilizes CRISPR/Cas9 technology delivered via lipid nanoparticles to permanently disrupt the LPA gene in hepatic tissue. If early phase 1 clinical trials confirm safety and specificity, in vivo gene editing could ultimately offer a one-time curative treatment for severe genetic elevations.

Current Pipeline of Novel Lipoprotein A Therapies in Clinical Practice

The rapid evolution of novel lipoprotein a therapies signals an imminent transformation in preventive cardiology. Major international clinical societies now recommend universal, once-in-a-lifetime screening for elevated levels, particularly among individuals with premature coronary disease or calcific aortic stenosis. Because South Asian populations face an elevated baseline risk of premature coronary artery disease, routine screening provides crucial risk stratification insights. Although definitive clinical practice updates await primary cardiovascular outcomes trial readouts, clinicians should aggressively optimize other modifiable risk factors in patients with elevated levels. Controlling blood pressure, optimizing blood glucose, and aggressively lowering low-density lipoprotein cholesterol remain essential interim strategies. As cardiovascular outcomes trials report findings over the next two years, regulatory approvals will reshape global dyslipidemia guidelines. In conclusion, clinicians should prepare for a paradigm shift where targeted pharmacotherapy addresses this longstanding residual cardiovascular risk.

How do novel lipoprotein a therapies differ from traditional lipid-lowering medications?

Traditional lipid-lowering drugs, such as statins and ezetimibe, primarily upregulate low-density lipoprotein receptors to clear circulating particles. However, these mechanisms do not effectively clear lipoprotein(a) because its clearance occurs independently of classic LDL receptors. In contrast, novel therapies directly inhibit the hepatic production of apolipoprotein(a) using RNA interference or block particle assembly using oral small molecules, achieving dramatic reductions of eighty to over ninety-five percent.

When should clinicians order lipoprotein(a) screening in routine clinical practice?

Current international guidelines recommend measuring lipoprotein(a) at least once in every adult lifetime to identify high-risk cardiovascular phenotypes. Screening is particularly critical for individuals with personal or family histories of premature cardiovascular disease, familial hypercholesterolemia, calcific aortic valve stenosis, or unexplained recurrent coronary events despite optimal statin therapy. Because concentrations remain genetically stable throughout adulthood, a single lifetime test provides reliable long-term risk assessment.

What should clinicians do for patients with elevated lipoprotein(a) while awaiting drug approvals?

While waiting for outcomes trial results and regulatory approvals, clinicians should focus on comprehensive cardiovascular risk reduction. Providers must aggressively manage all concomitant modifiable risk factors by lowering low-density lipoprotein cholesterol to strict target levels using high-intensity statins, ezetimibe, or PCSK9 inhibitors. Additionally, managing hypertension, controlling diabetes, promoting healthy dietary patterns, and considering antiplatelet therapy for secondary prevention remain essential clinical priorities.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Healthcare professionals must use their independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Ebubechukwu U et al. Novel Lipoprotein (a) Therapies: A Comprehensive Review. Curr Atheroscler Rep. 2026 Aug 13. doi: undefined. PMID: 42593611.
2. Granata LG, Giubilato S, Campanella F, et al. Lipoprotein(a) in cardiovascular disease: pathophysiology, residual risk, and emerging therapeutic strategies. Curr Opin Cardiol. 2026;41(2):145-154.
3. Almahmeed W, Sabbour H, Shantouf R, et al. Expert consensus on Lipoprotein(a): Navigating cardiovascular risk and therapeutic advances. Atheroscler Plus. 2026;65:100569.